A package of Beyfortus, in an undated file photograph. Fred Tanneau/AFP via Getty ImagesAn antibody that protects against respiratory syncytial virus (RSV) works well for one year but possibly not beyond, according to newly published research.Nirsevimab, the antibody, “may not be effective after 12 months of administration,” Japanese researchers reported in the study, which was published on Nov. 6 by the Journal of Infection.
Antibody Against RSV Prevents Cases for 1 Year: Study
Date:
